Home » Stocks » MITO

Stealth BioTherapeutics Corp. (MITO)

Stock Price: $1.52 USD -0.10 (-6.17%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.43 -0.09 (-5.92%) May 7, 7:59 PM
Market Cap 84.54M
Revenue (ttm) 21.09M
Net Income (ttm) -57.46M
Shares Out 55.62M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.52
Previous Close $1.62
Change ($) -0.10
Change (%) -6.17%
Day's Open 1.37
Day's Range 1.30 - 1.52
Day's Volume 10,548,151
52-Week Range 1.06 - 2.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Will these 3 penny stocks be on your Thursday morning watchlist? The post Top Penny Stocks For Your Thursday Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: LKCO, PRPO
1 day ago - PennyStocks

BOSTON, May 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies fo...

2 days ago - PRNewsWire

BOSTON, April 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...

1 week ago - PRNewsWire

BOSTON, April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...

1 week ago - PRNewsWire

BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...

1 month ago - PRNewsWire

BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

1 month ago - PRNewsWire

BOSTON, March 16, 2021 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for d...

1 month ago - PRNewsWire

BOSTON, March 2, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...

2 months ago - PRNewsWire

BOSTON, Feb. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...

2 months ago - PRNewsWire

BOSTON, Jan. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

4 months ago - PRNewsWire

BOSTON, Jan. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

4 months ago - PRNewsWire

BOSTON, Dec. 9, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

4 months ago - PRNewsWire

BOSTON, Nov. 24, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercia...

5 months ago - PRNewsWire

Stealth BioTherapeutics (MITO) CEO Reenie McCarthy on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

BOSTON, Nov. 5, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

6 months ago - PRNewsWire

BOSTON, Nov. 4, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

6 months ago - PRNewsWire

BOSTON, Oct. 30, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...

6 months ago - PRNewsWire

BOSTON, Oct. 19, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for di...

6 months ago - PRNewsWire

BOSTON, Sept. 23, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for d...

7 months ago - PRNewsWire

BOSTON, Sept. 10, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

7 months ago - PRNewsWire

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q2 2020 Earnings Call Transcript

8 months ago - Seeking Alpha

BOSTON, May 26, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...

11 months ago - PRNewsWire

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

11 months ago - Zacks Investment Research

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Stealth BioTherapeutics Corp. (NASDAQ: MITO) stock more than doubled on Tuesday after the company announced a critical update from the U.S.

1 year ago - 24/7 Wall Street

Shares of Stealth BioTherapeutics MITO, -63.94% tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mut...

1 year ago - Market Watch

Stealth BioTherapeutics Corp. (NASDAQ: MITO) shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy.

1 year ago - 24/7 Wall Street

About MITO

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's heredit... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2019
Stock Exchange
NASDAQ
Ticker Symbol
MITO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for MITO stock is "Buy." The 12-month stock price forecast is 3.33, which is an increase of 119.08% from the latest price.

Price Target
$3.33
(119.08% upside)
Analyst Consensus: Buy